Bilayer tablet formulation of metformin hydrochloride and glipizide: A novel approach in the treatment of diabetes

International Journal of Pharmaceutical Sciences Review and Research

Volumn 8, Issue 2, 2011, Pages 209-215

  Bagyalakshmi, J ^a   Krishna, Y Phani ^a   Ravi, T K ^a  

^a SRI RAMAKRISHNA INSTITUTE OF PARAMEDICAL SCIENCES   (India)

Author keywords

Bilayer tablet; Glipizide; HPMC; Metformin hydrochloride

Indexed keywords

DRUG CARRIER; GLIPIZIDE PLUS METFORMIN; STARCH GLYCOLATE SODIUM;

ARTICLE; BILAYER MEMBRANE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG SOLUBILITY; DRUG SYNTHESIS; EXCIPIENT COMPATIBILITY; IN VITRO STUDY; INFRARED SPECTROSCOPY; MATRIX TABLET; NON INSULIN DEPENDENT DIABETES MELLITUS; PH MEASUREMENT; SUSTAINED RELEASE FORMULATION; TABLET FORMULATION;

EID: 80052692578     PISSN: None     EISSN: 0976044X     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Tripathi KD. Essentials of Medical pharmacology: Jaypeee Brothers Medical Publishers Pvt, Ltd. New Delhi, India; 2004. p. 235-253.
2. Bailey CJ, Turner RC: Metformin. N Engl J Med 334: 574-579, 1996.
3. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE: Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 333: 550-554, 1995.
4. DeFronzo RA, Goodman AM: Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 333: 541-549, 1995.
5. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B: Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29:1963-1972, 2006.
6. Salpeter SR, Walsh JM, Ormiston TM, Greyber E, Buckley NS, Salpeter EE: Meta-analysis: effect of hormonereplacement therapy on components of the metabolic syndrome in postmeno-pausal women. Diabetes Obes Metab 8: 538-554, 2006.
7. Dunn C J, Peters DH. Metformin: A review of its pharmacological properties and therapeutic use in noninsulin dependent diabetes mellitus. Drugs. 1995; 49:721-749.
8. Defang O, Shufang N, Wei L. In vitro and in vivo evaluation of two extended release preparations of combination metformin and glipizide. Drug Dev. Ind. Pharm. 2005; 31: 677-685.
9. Scheen AJ. Clinical pharmacokinetics of metformin. Clin. Pharmacokinet. 1996; 30: 359-371.
10. Schwartz S, Fonseca V, Berner B, Cramer M, Chiang YK, Lewin A: Efficacy, tolerability, and safety of a novel oncedaily extended-release Metformin in patients with type 2 diabetes. Diabetes Care 29:759-764, 2006.
11. Gangji AS, Cukierman T, Gerstein HC, Goldsmith CH, Clase CM: A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care 30: 389-394, 2007.
12. Siconolfi-Baez L, Banerje MA, Lebovitz HE. Characterization and significane of sulfonylurea receptors. Diabetes Care. 1990; 13; 2-8.
13. Hogan JE. Hydroxypropyl methylcellulose sustained release technology. Drug Dev. Ind pharm. 1989; 15: 975-999.
14. Mutalik S, Hiremath D. Formulation and evaluation of chitosan matrix tablets of nifedipine. The Eastern Pharmacist. 2000; 2: 109-111.
15. Korsmeyer RW, Gurny R, Doelker E. Mechanism of solute release from porous hydrophilic polymers. International journal of Pharmaceutical sciences. 1983; 15: 25-35.
16. Fassihi RA, Ritschel WA. Multiple layer, direct-compression controlled-release system: In vitro and in vivo evaluation. J. Pharm Sci. 1993; 82: 750-754.
17. Peppas NA. Analysis of Fickian and non-Fickian drug release from polymers. Pharm. ActaHelv. 1985; 60: 110-111.